baber/WOPTO huggingface dataset:
Patent NZ-334127-A (NZ)
Title: Cryptophycin compounds which disrupt microtubulin systems
Inventor: AL-AWAR RIMA S
IPC: C07D273/08
Filed: 1997-08-29
Abstract: The cryptophycin compounds of formula I disrupt microtubulin systems. The compounds can be used as anti-neoplastic agents and for treating fungal infections. In formula I; Ar is selected from the group consisting of phenyl, any simple unsubstituted aromatic, simple substituted aromatic, optionally substituted heteroaromatic group, heterocyclic, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, NR51R52, COR52, OR53 or other group; wherein R51 is selected from the group consisting of hydrogen and C1-3 alkyl; R52 is selected from the group consisting of hydrogen and C1-3 alkyl; R53 is selected from the group consisting of C1-12 alkyl; R1 and R2 are each independently selected from the group consisting of halogen, monalkylamino, dialkylamino, trialkylammonium, alkylthio, dialkylsulfonium, sulfate, phosphate, or OR31, SR31, NR31, OH, SH, or other group; wherein R31is P, S, C1-12 alkyl, B, an amino acid or other group; or R1 and R2 may be taken together with C-18 and C-19 to form an epoxide ring, an aziridine ring, an episulfide ring, a sulfate ring, a cyclopropyl ring or mono(C1-6)alkyl-phosphate ring; or R1 and R2 may be taken together to form a second bond between C-18 and C-19; R3 is a lower alkyl group; R4 is H or OH; R5 is H or OH; or R4 and R5 may be taken together to form a second bond between C13 and C14; R6 is a substituent selected from the group consisting of benzyl, hydroxybenzyl, alkoxybenzyl, halohydroxybenzyl, dihalohydroxybenzyl, haloalkoxybenzyl, or dihaloalkyoxybenzyl group, B-ring heteroaromatic, substituted heteroaromatic, B-ring (C1-6 alkyl, (C3-8) cycloalkyl, substituted C3-8 cycloalkyl, substituted (C1-6) alkyl, or other group; R7 is selected from the group consisting of NR51R52, R53NR51R57, OR53, H and a lower alkyl group; wherein R57 is H, halogen or C1-12 alkyl; R8 is H or a lower alkyl group; or R7 and R8 can form a cyclopropyl ring; R9 is selected from the group consisting of H, a lower alkyl group, unsaturated lower alkyl, lower alkyl-C3-5 cycloalkyl, and benzyl; R10 is H or a lower alkyl group; R11 is selected from the group consisting of hydrogen, OH, lower alkyl group, optionally substituted phenyl, or optionally substituted benzyl; Rl4 is selected from the group consisting of hydrogen and lower alkyl; R30 is hydrogen or C1-6 alkyl; or R30 may be taken together with the N at C-ll to form a 3 to 7 membered cyclic ring; R50 is hydrogen or a carbonyl group; X is selected from the group consisting of 0, C, S, NH and alkylamino; and Y is selected from the group consisting of C, O, NH, S, SO, SO2 and alkylamino.
Patent NZ-335547-A (NZ)
Title: Apparatus having electrolyte and electrodes to function as battery to drive fan motor to disperse fragrance in electrolyte
Inventor: SMITH NIGEL PETER
IPC: A61L9/12
Filed: 1997-10-22
Abstract: An apparatus is disclosed for dispersing an air modifying agent (e.g. a fragrance) in air. The air modifying agent and an electrolyte are entrained in a gel-based aqueous reservoir (7), which contacts a pair of electrodes (8, 9) which are "+ve" and "-ve" with respect to each other to provide an electrical potential between the electrodes. The electrical potential powers a small motor and fan (13, 14) which disperse the air modifying agent from the surface of the reservoir (7) to the surrounding atmosphere via apertures (16) in a housing (10) of the apparatus. The electrical potential can power additional or alternative electrical devices such as lighting and heating devices, and the arrangement may be such that the extent of exhaustion of the air modifying agent from the reservoir (7) corresponds generally to the extent of exhaustion of electrode (8, 9) activity, whereby the operability of the electrical device indicates the presence of air modifying agent in the reservoir (7).
Patent NZ-335676-A (NZ)
Title: Coated particles comprising an exterior coating and a matrix comprising a liquid phase or liquid crystalline phase which is nanostructured
Inventor: ANDERSON DAVID M
IPC: B32B27/00
Filed: 1998-09-08
Abstract: [ A coated particle is that comprises an internal core comprising a matrix and an exterior coating. The matrix consists essentially of at least one nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two and the exterior coating comprising a non-lamellar crystalline material. Methods of making and methods of using the coated particle are disclosed.
Patent NZ-337857-A (NZ)
Title: Mobile checking of optical reflectivity of road markers
Inventor: GALLAGHER PHILIP ANTHONY
IPC: G01N21/55
Filed: 1998-03-05
Abstract: Reflectivity measuring apparatus for assessing the integrity of road markings includes a light source 4, a light sensor 6 and a processor 8.  The apparatus is mounted on a vehicle such that, in use, the light source illuminates a reflective surface on a road marking 2, and wherein the light sensor detects any reflected light and the data signal is received by the processor, the processor processes the data to provide information on the reflectivity of a said reflective surface.  To enable the vehicle driver to keep the light source and sensor positioned over the road markers as the vehicle is being driven along the road, the processor controls an audible indicator or visual display 11 to indicate to the driver the location of the road markings relative to the vehicle.
Patent NZ-502168-A (NZ)
Title: Inducing and maintaining a CTL response by delivering antigen to the lymphatic system of a mammal via an external apparatus
Inventor: SIMARD JOHN L
IPC: A61P31/04
Filed: 1998-07-10
Abstract: A method of inducing and sustaining or sustaining an immunologic cytotoxic T-lymphocyte (CTL) response to an antigen is disclosed.  The method involves delivering the antigen to the lymphatic system of an animal regularly over a sustained period of time using, e.g., an osmotic pump.  The method does not require repetitive immunizations or the use of adjuvants.  It can also be used for the induction of CTLs in tumour or infectious disease immunotherapy.
Patent NZ-505323-A (NZ)
Title: Phenalenyl, acenaphthyl and other tricyclic compounds
Inventor: LANGLOIS MICHEL
IPC: C07C233/60
Filed: 1998-12-11
Abstract: A compound of formula (I) or the enantiomers and diastereoisomers and addition salts thereof  wherein: A forms with the group to which it is bonded a tricyclic system selected from A1, A2, A3 and A4; R1 is hydrogen, halogen, alkyl, alkoxy, hydroxy or oxo; R2 and R3 are independently halogen, Ra, ORa, CORa, OCORa or COORa with the symbols (R2)m and (R3)m' denote that the ring in question may be substituted by from 1 to 3 groups (which may be the same or different) belonging to the definitions for R2 and R3; Ra is hydrogen, trihaloalkyl or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or aryl; X, when A is a tricyclic A1, A2, A3 and A4, is sulphur, (CH2)q -CH=CH-, or NR4 or X is oxygen when A is the tricyclic system A1 and n is an integer such that 0[n[3 or p is an integer such that 1[p[3 when n is 1, 2 or 3 and the chain of formula B' is in the b position and A is either A2, A3 or A4  and X is -CH=CH- or A is the group A1, and such that 0[p[3; in all other cases, it is possible for the chain of formula B' chain to be optionally substituted; R4 is hydrogen or optionally substituted alkyl; q is 1 or 2; B is NRa-C(=Z)-R5 Z is oxygen or sulphur; R5 is Ra or NR6R7 or -(C=Z)-NR6R7; R6 and R7 are independently Ra or with the proviso that: when the tricyclic group of formula A1 is a 6-methoxy-tetrahydro-benzo[cd]indole, B cannot represent NHCOMe and the compound of formula (I) is not:  N-(4-methyl-2,3-dihydro-1H-1-phenalenyl)-1-cyclopropanecarboxamide; N-(4-methyl-2,3-dihydro-1H-1-phenalenyl)-2-chloroacetamide; 2-methyl-1,3,4,5-tetrahydrobenzo[cd]indole-3-carboxamide;  N-(5-hydroxy-1,2,2a,3,4,5-hexahydro-4-acenaphthylenyl)acetamide; N-(5-hydroxy-1,2,2a,3,4,5-hexahydro-4-acenaphthylenyl)benzamide or N-(1,2,2a,3,4,5-hexahydro-4-acenaphthylenyl)acetamide. The compounds of formula (I) are useful for treating conditions of the central nervous system.
Patent NZ-505896-A (NZ)
Title: Method and apparatus for assessing or predicting characteristics of wood or other materials by varying frequency of acoustic transmitter and sensing a response
Inventor: HARRIS PAUL DAVID
IPC: G01N33/46
Filed: 2000-07-21
Abstract: A method and apparatus for acoustically assessing or predicting a characteristic of a wood specimen to assist in optimising the use of the specimen.  The method includes: exciting the specimen with a frequency varying excitation to impart an acoustic wave into the specimen; sensing a response indicative of the acoustic wave behaviour within the specimen; determining a response characteristic of the specimen by signal processing the sensed response; determining at least one resonant frequency of the specimen from the response characteristic; determining an acoustic velocity in the specimen from the at least one resonant frequency; and determining the characteristic using the acoustic velocity.  The apparatus includes: a transmitting transducer for coupling to the specimen for generating a frequency varying excitation to impart an acoustic wave in the specimen; a first receiving transducer adapted to sense a response indicative of the behaviour of an imparted acoustic wave; and signal processing means adapted for determining a response characteristic from the sensed response, and for determining at least one resonant frequency of the specimen from the response characteristic.  The processing means is further adapted for determining an acoustic velocity in the specimen from the at least one resonant frequency, and for determining the characteristic using the acoustic velocity.
Patent NZ-509304-A (NZ)
Title: Processes for coupling amino acids using BIS-(trichloromethyl) carbonate
Inventor: FALB ELIEZER
IPC: C07K1/08
Filed: 1999-07-11
Abstract: A process of coupling an amino acid residue to a peptide chain which comprises: (i) providing an amino acid residue having a free carboxylic group and blocked amino group, optionally having additional blocked functional side chains; (ii) reacting the blocked amino acid with bis-(trichloromethyl)carbonate in a solvent inert to this reaction to obtain an amino acid chloride; (iii) neutralising the free acid with an organic base; (iv) adding the resulting suspension containing the amino acid chloride to a compound selected from the group consisting of a peptide having a blocked carboxyl terminus and a free amino terminus, and a peptidyl resin having at least one free amino terminus; and (v) providing reaction conditions enabling the coupling of the amino acid chloride to the peptide to yield a peptide, other than an aza analogue of a peptide, elongated by one amino acid residue.
Patent NZ-511304-A (NZ)
Title: Closure device for a membrane sealed container where the top wall of the closure has an arcuate pierce plow member
Inventor: LOUGHRIN THOMAS D
IPC: B65D51/22
Filed: 1999-11-08
Abstract: A cap member having an annular wall and a top wall disposed within and connected to the annular wall. An arcuate pierce-plow member is disposed on an upper surface of the top wall at a position spaced from the annular wall. The pierce-plow member includes a first plow base member having a ramp portion and a substantially flat portion. The pierce-plow member further includes a piercing member disposed adjacent to the substantially flat portion of the plow base member. The piercing member includes a first portion disposed adjacent to the first plow base member and a second portion disposed at a position spaced from the first plow base member. A thickness of the second portion of the piercing member is greater than a thickness of the first portion of the piercing member.
Patent NZ-513217-A (NZ)
Title: Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
Inventor: WONG PANCRAS C
IPC: A61K38/02
Filed: 2000-03-10
Abstract: A method of treating thrombosis in a non-human patient comprising administering to the patient a therapeutically effective amount of a combination of (i) a non-peptide Factor Xa inhibitor, and (ii) aspirin, wherein the does administered for at least one of (i) and (ii) is a subtherapeutic dose and wherein the combinations of (i) and (ii) provides a synergistic effect. Also disclosed is the above combination for the manufacture of a medicament for the treatment of thrombosis.
Patent NZ-515866-A (NZ)
Title: Therapeutic use of melatonin
Inventor: ZISAPEL NAVA
IPC: A61K31/5513
Filed: 2000-05-24
Abstract: A pharmaceutical formulation which comprises, in addition to at least one carrier, diluent or adjuvant, at least one neuroleptic compound in an amount effective to exert a neuroleptic effect in a patient requiring such treatment, and melatonin in an amount effective to ameliorate or prevent  symptoms of tardive dyskensia developing in the patient.
Patent NZ-517044-A (NZ)
Title: Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
Inventor: GUTTUSO THOMAS J JR
IPC: A61K31/195
Filed: 2000-07-21
Abstract: The use of a compound which binds a á2ä subunit of a voltage-gated calcium channel in the preparation of a medicament for treating hot flushes in a patient and/or hormonal variation. Further described is the use of a compound which binds a á2ä subunit of a voltage-gated calcium channel in the preparation of a medicament for treating fever.
Patent NZ-518562-A (NZ)
Title: Novel methods and compositions involving opioids and antagonists thereof
Inventor: FARRAR JOHN J
IPC: A61K31/445
Filed: 2000-11-29
Abstract: Compositions comprising opioids and opioid antagonists are disclosed. In preferred embodiments, the compositions comprise opioids and peripheral mu opioid antagonist compounds. These compositions are particularly suitable for treating and/or preventing side effects associated with opioids including, for example, constipation, vomiting and/or nausea.
Patent NZ-533803-A (NZ)
Title: Device to clamp to tow ball of vehicle with cantilevered supports pivotable from respective uprights
Inventor: LUCAS DAVID REX
Filed: 2004-06-28
Abstract: Uprights 101,103 are connected via members 105 and hinged members 125,127. Locking pin 156 (or a padlock not shown) is used to lock the device onto the ball of a vehicle tow bar. Supports 111, 113 are hinged to the uprights so as to pivot outwardly as shown or be swung over and flat against the uprights.
Patent NZ-536238-A (NZ)
Title: Method and device for efficient frame erasure concealment in linear predictive based speech codecs
Inventor: JELINEK MILAN
IPC: G10L19/005
Filed: 2003-05-30
Abstract: A method and device are disclosed for improving concealment of frame erasure caused by frames of an encoded sound signal erased during transmission from an encoder (106) to a decoder (110), and for accelerating recovery of the decoder after non-erased frames of the encoded sound signal have been received. Concealment/recovery parameters are determined in the encoder or decoder. When determined in the encoder (106), the concealment/recovery parameters are transmitted to the decoder (110). In the decoder, erasure frame concealment and decoder recovery is conducted in response to the concealment/recovery parameters. The concealment/recovery parameters may be selected from the group consisting of: a signal classification parameter, an energy information parameter and a phase information parameter. The determination of the concealment/recovery parameters comprises classifying the successive frames of the encoded sound signal as unvoiced, unvoiced transition, voiced transition, voiced, or onset, and this classification is determined on the basis of at least a part of the following parameters: a normalized correlation parameter, a spectral tilt parameter, a signal-to-noise ratio parameter, a pitch stability parameter, a relative frame energy parameter, and a zero crossing parameter.
Patent NZ-537434-A (NZ)
Title: Managing group calls in a mobile radio system via a priority parameter
Inventor: NISBET REX ALLEN
IPC: H04L12/56
Filed: 2003-07-04
Abstract: A method of operating a base station in a packet network during a group call between mobile units is described. The method includes the steps of receiving a signal from a mobile unit in the group call, determining a priority parameter for the received signal, adding the parameter to at least some packets of the received signal and transmitting the signal containing the priority parameter to the network. When the base station receives signals containing respective priority parameters from two or more other base stations in the network, one of the received signals is selected according to the received priority parameters and the selected signal is transmitted to units in the group call.
Patent NZ-538297-A (NZ)
Title: Use of IkB kinase inhibitors for the treatment of pain
Inventor: MICHAELIS MARTIN
Filed: 2003-08-05
Abstract: Disclosed are IkappaB inhibitors that are suitable for producing medicaments for the treatment of pain. Suitable inhibitors are produced from compounds of formulas (I) and (Ia) and can be utilised in the prophylaxis and therapy of acute pains e.g. pains following injuries, post-operative pains or chronic pains e.g. pains associated with menstruation, osteoarthritis, multiple sclerosis, or neuropathic pains.
Patent NZ-540143-A (NZ)
Title: Cohesive demineralized bone compositions
Inventor: ROSENBERG ARON D
IPC: A61L27/50
Filed: 2003-11-14
Abstract: Demineralized bone matrix fibers and a demineralized bone matrix composition are provided. The demineralized bone matrix fibers have an average fiber length in the range from about 250 micrometres to about 2 millimetres and an aspect ratio of greater than about 4. The demineralized bone matrix composition includes demineralized bone matrix fibers and a biocompatible liquid in an amount to produce a coherent, formable mass. The formable mass retains its cohesiveness when immersed in a liquid. Methods for making the demineralized bone matrix fibers and composition are also provided.
Patent NZ-544485-A (NZ)
Title: Cannula/catheter introducer with retractable needle
Inventor: RODD AARON
IPC: A61M25/06
Filed: 2004-07-30
Abstract: A device is disclosed that allows a puncture needle to be inserted into a catheter. Once the puncture needle has performed its function, it can shoot back into the device such that there is a reduce likelihood of needlestick injury. Vacuum is used to assist in the shoot back function.
Patent NZ-544520-A (NZ)
Title: Gantry with auto-adjusting prestressing
Inventor: PACHECO PEDRO ALVARES RIBEIRO
IPC: E01D21/00
Filed: 2004-06-03
Abstract: A gantry for use in the construction process of bridges, viaducts and other structures is disclosed. The gantry is equipped with a system that automatically adjusts the pre-stressing of the gantry's structure (1) in accordance with external actions being applied on it when loadings occur. The adjustment of the pre-stressing is achieved through the use of a controller (6) that receives signals from at least one sensor (2) that monitors the structure, and activates at least one actuator which alters the tension of the structure's pre-stressing cable or cables (5). A large amount of pre-stressing is able to be applied without undesirable deformations arising in the main structure (1) when exterior loads are not applied.
Patent NZ-548578-A (NZ)
Title: Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
Inventor: PLATA-SALAMAN CARLOS
IPC: A61P9/00
Filed: 2002-01-24
Abstract: Provided is the use of a fructopyranose sulfamate (including topiramate) and erythropoietin (including epoetin alfa) in the preparation of a medicament for treating a neurological dysfunction in a subject in need thereof, wherein the amount of the fructopyranose sulfamate and the amount of the erythropoietin to be administered are selected to produce a synergistic effect. The neurological dysfunction to be treated include acute neurodegenerative disorders and chronic neurodegenerative disorders. Further provided are specific dosages and diseases to be treated.
Patent NZ-548720-A (NZ)
Title: Installation with support means for driving a lift cage, and corresponding support means
Inventor: ACH ERNST
Filed: 2006-07-24
Abstract: A lift installation (10) with support means (13) and drive pulley (16) for driving the support means (13), wherein the support means (13) at least partly loops around the drive pulley (16), the support means (13) comprises a safety section (17) which produces a slipping through by interaction between the drive pulley (16) and the safety section (17) of the support means (13), wherein the support means (13) is a belt-like support means characterised in, that the belt-like support means (13) comprises a traction-reducing coating in the region of the safety section (17).
Patent NZ-552313-A (NZ)
Title: Beverage container valve assembly with dispensing member attachable to container neck and having flexible seal with slit(s), and a cover member
Inventor: BEALE GLENN ROBERT
Filed: 2006-12-22
Abstract: The beverage container valve assembly 10 has a dispensing member 12 with a tamper evident lower portion, and a flexible seal 32 having at least one slit 38. A cover member 14 overlies member 12 hand also has a tamper evident lower portion.
Patent NZ-553634-A (NZ)
Title: Wheyless process for the production of mozzarella string cheese using dry dairy ingredients
Inventor: LINCOURT RICHARD HAROLD
Filed: 2005-09-09
Abstract: Disclosed is a method for preparing mozzarella string cheese from dry dairy ingredients, the method comprising: (1) mixing water and a dairy fat to form a first blend; (2) adding a proteolytic enzyme to the first blend; (3) adding a lactic acid-producing culture to the first blend to form a second blend; (4) mixing a dry dairy ingredient with the second blend to form a cultured dairy blend, wherein the dry dairy ingredient comprises a milk protein concentrate or a blend of the milk protein concentrate and up to about 50 percent of a second dry dairy ingredient selected from the group consisting of whey protein concentrate, whey protein isolate, calcium caseinate, sodium caseinate, rennet casein, acid casein, nonfat dry milk, proteinaceous dairy material, and mixtures thereof, and wherein the milk protein concentrate has a solubility of greater than about 50 percent and a whey protein content of less than about 15 percent; (5) incubating the cultured dairy blend at a temperature and for a time sufficient to obtain a pH of about 4.8 to less than 5.2; (6) mechanically working and cooking the cultured dairy blend from step (5) in a cooker at a temperature ofabout 150 to about 175°F and under relatively low shear conditions; (7) forming the dairy blend under relatively low shear conditions to form the mozzarella string cheese; and (8) collecting the mozzarella string cheese, wherein the process does not include the formation of whey, wherein the mozzarella string cheese does not contain significant levels of added emulsifying salts, and wherein the mozzarella string cheese has texture and organoleptic properties comparable to a natural mozzarella string cheese prepared in a conventional mozzarella process.